Pharmaxis closer to US approval for its Bronchitol drug
Sydney biotech drug developer and manufacturer, Pharmaxis (ASX: PXS) has secured a positive recommendation from a key US body for the benefits of its flagship Bronchitol drug in the treatment of adult cystic fibrosis. The decision, from the Pulmonary‐Allergy Drugs Advisory Committee (PADAC), supported the approval for the use of the inhaled dry powder for…